We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$5.41M
Cap. Flow
+$2.38M
Cap. Flow %
0.66%
Top 10 Hldgs %
7.17%
Holding
495
New
34
Increased
285
Reduced
131
Closed
45

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$2.11M
2
HSY icon
Hershey
HSY
+$2.09M
3
GILD icon
Gilead Sciences
GILD
+$2.07M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.05M
5
EIX icon
Edison International
EIX
+$2.04M

Top Sells

Rank Stock Value
1
HBAN icon
Huntington Bancshares
HBAN
+$2.13M
2
TKO icon
TKO Group
TKO
+$2.13M
3
WAT icon
Waters Corp
WAT
+$2.09M
4
STT icon
State Street
STT
+$2.07M
5
AON icon
Aon
AON
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Financials 20.97%
3 Technology 10.66%
4 Industrials 10.62%
5 Consumer Discretionary 7.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
151
Krystal Biotech
KRYS
$9.65B
$891K 0.25%
3,449
+657
+24% +$175K
LGND icon
152
Ligand Pharmaceuticals
LGND
$6.06B
$889K 0.25%
4,453
+848
+24% +$168K
BIIB icon
153
Biogen
BIIB
$29.6B
$889K 0.25%
4,848
+925
+24% +$170K
EXEL icon
154
Exelixis
EXEL
$14B
$886K 0.24%
20,651
+3,935
+24% +$169K
PSEC icon
155
Prospect Capital
PSEC
$1.06B
$882K 0.24%
337,946
-122,843
-27% -$336K
HALO icon
156
Halozyme
HALO
$9.59B
$877K 0.24%
13,571
+2,587
+24% +$182K
ASND icon
157
Ascendis Pharma A/S
ASND
$16.6B
$876K 0.24%
3,830
+730
+24% +$164K
SRPT icon
158
Sarepta Therapeutics
SRPT
$1.68B
$853K 0.24%
39,213
+7,472
+24% +$145K
BBIO icon
159
BridgeBio Pharma
BBIO
$16.2B
$834K 0.23%
11,234
+2,141
+24% +$155K
ARDX icon
160
Ardelyx
ARDX
$1.27B
$814K 0.22%
135,954
+25,906
+24% +$171K
BNTX icon
161
BioNTech
BNTX
$23.3B
$791K 0.22%
8,904
+1,697
+24% +$174K
AUPH icon
162
Aurinia Pharmaceuticals
AUPH
$1.96B
$789K 0.22%
53,267
+10,150
+24% +$148K
GSBD icon
163
Goldman Sachs BDC
GSBD
$969M
$788K 0.22%
88,738
-11,151
-11% -$103K
ONC
164
BeOne Medicines Ltd
ONC
$33.9B
$786K 0.22%
2,646
+505
+24% +$163K
IONS icon
165
Ionis Pharmaceuticals
IONS
$9.23B
$784K 0.22%
10,445
+1,991
+24% +$157K
MDGL icon
166
Madrigal Pharmaceuticals
MDGL
$12.5B
$773K 0.21%
1,476
+282
+24% +$135K
PTCT icon
167
PTC Therapeutics
PTCT
$6.51B
$760K 0.21%
11,160
+2,127
+24% +$151K
ARWR icon
168
Arrowhead Research
ARWR
$12.2B
$755K 0.21%
12,045
+2,296
+24% +$145K
TBPH icon
169
Theravance Biopharma
TBPH
$874M
$754K 0.21%
46,464
+8,853
+24% +$157K
PNNT
170
Pennant Park Investment Corp
PNNT
$212M
$743K 0.21%
165,540
+42,374
+34% +$225K
FSK icon
171
FS KKR Capital
FSK
$2.96B
$735K 0.2%
72,227
+9,306
+15% +$116K
OCSL icon
172
Oaktree Specialty Lending
OCSL
$1.02B
$730K 0.2%
64,582
+103
+0.2% +$1.23K
TARS icon
173
Tarsus Pharmaceuticals
TARS
$2.56B
$728K 0.2%
10,378
+1,979
+24% +$138K
NBIX icon
174
Neurocrine Biosciences
NBIX
$17.5B
$728K 0.2%
5,524
+1,052
+24% +$140K
TVTX icon
175
Travere Therapeutics
TVTX
$5.27B
$720K 0.2%
24,239
+4,619
+24% +$138K
5 6
7
8 9

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
MA
Modus Advisors Excelsior, Minnesota $363M AUM 22.99% 1-Year Est. Return

Virtus Investment Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, Virtus Investment Advisers held 495 positions worth $363M, down 1.5% from $368M the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.

Virtus Investment Advisers's Q1 2026 filing shows 34 new, 285 increased, 131 reduced and 45 closed positions. Its largest new stake was Hershey: 9,903 shares worth $2.06M. The largest sale was Huntington Bancshares, an estimated $2.13M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Financials and Technology.

  • Virtus Investment Advisers's largest Q1 2026 buy was Hershey: 9,903 shares worth $2.06M.
  • Virtus Investment Advisers added most to Amgen in Q1 2026, an estimated $2.11M increase.
  • Virtus Investment Advisers's biggest Q1 2026 reduction was Micron Technology, cutting an estimated $1.56M.
  • Virtus Investment Advisers fully exited Huntington Bancshares in Q1 2026, selling an estimated $2.13M.
  • Virtus Investment Advisers's ten largest holdings make up 7.2% of its $363M portfolio in Q1 2026.
  • Virtus Investment Advisers opened 34 new positions and closed 45 in Q1 2026.
  • Virtus Investment Advisers's portfolio value fell 1.5% quarter-over-quarter to $363M.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.